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INTRODUCTION
Diabetes mellitus is characterized by hyperglyce-
mia and caused by the inadequate insulin secretion 
from pancreatic beta cells or by the insufficient 
utilization of the secreted insulin. According to 
the International Diabetes Federation, one in every 
11 adults is having diabetes, resulted in 5 million 
deaths in 2015. Autoimmune-mediated destruction 
of pancreatic beta cells causes type 1 diabetes melli-
tus (T1DM), which is also known as  juvenile-onset 
diabetes. Whereas, the type 2 diabetes mellitus 
(T2DM), also known as adult onset diabetes, 
commonly linked with obesity, and accounts for 
>95% of diabetes cases worldwide, is associated 
with insulin resistance due to the improper utiliza-
tion of glucose, and insulin deficiency due to the 
dysfunction of pancreatic beta cells.
Although exogenous insulin and oral hypogly-
cemic agents are helpful in decreasing the blood 
glucose level in diabetic patients, these agents 
can result in hypoglycemic coma, and they are 
not capable of mimicking endogenously secreted 
insulin, which provides a tight control over the 
blood glucose level. While the whole pancreas 
transplant or islet transplantation is an option to 
achieve post-operative insulin-independence, the 
 mortality associated with the surgery, and the life-
long immunosuppression and the availability of 
donor tissue remains an issue. Considering these, 
a better therapeutic option would be to expand the 
existing beta- cells within the body or by supplying 
exogenous insulin-producing stem cells.
For the treatment of T1DM and T2DM, 
several sources of stem cells, such as, embry-
onic stem cells, induced pluripotent stem cells, 
bone marrow-derived hematopoietic stem cells, 
bone  marrow-derived mesenchymal stem cells 
(MSCs), umbilical cord blood-derived MSCs, 
adipose tissue-derived MSCs, pancreas-derived 
multipotent precursor and progenitor cells 
etc. have been employed.1,2 However, MSCs are 
widely studied source of stem cells for the treat-
ment of diabetes mellitus, mainly due to their 
immunomodulatory and low-immunogenic 
characteristics, and besides, they can be isolated 
from various tissues.3 The current review will 
focus on the therapeutic potential of MSCs in 
treating diabetes mellitus.
MSCs for Diabetes Mellitus
The main characteristics of MSCs are their ability 
for self-renewal, immunomodulation, and differen-
tiation into tissues of mesodermal origin. Although, 
they can be found in many postnatal organs and 
tissues, they are frequently isolated from bone 
marrow, adipose tissue, and umbilical cord blood. 
MSCs show a variable expression levels of CD105, 
CD73, stromal antigen-1, CD44 and CD90 etc, 
but, lacking the hematopoietic cell markers such as 
CD14, CD45 and CD31 etc.4 Since the year 2005, 
the number of publications associated with MSCs 
for the treatment of diabetes have been increased 
constantly. The number of clinical trials associ-
ated with ‘mesenchymal stem cells AND diabetes’ 
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ABSTRACT
While exogenous insulin and oral hypoglycemic agents are helpful in 
controlling the blood glucose level in diabetic patients, these agents 
are occasionally resulted in hypoglycemic coma. Considering the 
epidemiology of the diabetic population in the world, we require a 
better therapeutic strategy like expanding the existing beta- cells 
within the body or by supplying exogenous insulin-producing stem 
cells. A variety of stem cells have been tested for the treatment of 
type 1 and type 2 diabetes mellitus, and among them, mesenchymal 
stem cells (MSCs) are widely used because of their immunomodulatory 
and low-immunogenic characteristics. So far, eight clinical trials have 
been completed using MSCs for the treatment of diabetes mellitus. 
Although the results of the currently available clinical trials are 
encouraging, i.e.  in improving function of the pancreatic beta cells 
and in controlling the complications associated with diabetes, we 
require larger, randomized, and double-blinded studies, with a longer 
duration of follow-up, to validate the findings obtained.  
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according to the website ClinicalTrials.gov, is 47, as 
of now, and of which, 8 studies have already been 
completed. 
The prospective clinical study of Carlsson et al5 
showed that the treatment with bone marrow-de-
rived mesenchymal stromal cells in 20 adult 
patients with newly diagnosed type 1 diabetes was 
found to be safe, and preserved the β-cells func-
tion, measured via C-peptide concentrations in 
the blood, in response to a mixed-meal tolerance 
test at 1-year follow-up. Although this study results 
are encouraging, it necessitates a larger study with 
a longer duration of follow-up. In contrast to the 
study of Carlsson et al, who involved the newly 
diagnosed type 1 diabetic patients, the study of Cai 
et al6 involved established type 1 diabetic patients, 
and using umbilical cord-derived mesenchymal 
stromal cells along with autologous bone marrow 
mononuclear cells transplantation, importantly, 
without immunotherapy, showed only a moder-
ate improvement in insulin secretion at 1-year 
follow-up. In type 2 diabetic patients, intravenous 
infusion of adult allogeneic bone marrow-derived 
mesenchymal precursor cells was found to be safe 
at 12 weeks, and a level of <7% HbA1c was achieved 
in 8 out of 45 patients at 12-weeks period.7 
Zhao et al8 attempted an interesting therapy, 
where the T1DM patient’s lymphocytes are sepa-
rated from the whole blood and briefly co-cultured 
them with adherent human cord blood-derived 
multipotent stem cells, before sending them back 
to the patient’s circulation. This ‘educator’ therapy 
reversed the autoimmunity, promoted the regen-
eration of islet β cells and markedly improved 
C-peptide levels. 
Lee et al9 have studied the effect of human 
bone marrow-derived MSCs (hMSCs) in experi-
mental diabetes using NOD/scid mice. In which, 
 intra-cardiac infusion of hMSCs reduced the blood 
glucose level in mice through an increase in pancre-
atic beta cells and islets, resulted in producing mouse 
insulin. In addition, there was an improvement in 
renal lesion through decreased mesangial thicken-
ing and macrophage infiltration in the kidneys. 
Pancreatic duodenal homeobox 1 (Pdx1) plays a 
key role in the differentiation of various  non-β-cells 
into insulin-producing cells, and Karnieli et al 
generated insulin-producing cells from human bone 
marrow mesenchymal stem cells through transduc-
tion of Pdx1 gene.10 In another study, human bone 
marrow-derived MSCs have been differentiated into 
insulin-producing cells through a differentiation 
protocol using high glucose, nicotinamide, and exen-
din-4. Importantly, these cells exhibited changes in 
the level of intracellular Ca2+ in response to glucose 
stimulation, as that seen in pancreatic β-cells in 
response to glucose-stimulated insulin secretion. 
Furthermore, transplantation of these in-vitro 
differentiated cells into  streptozotocin-induced 
diabetic nude mice produced human insulin.11
Bassi et al12 injected the adipose-derived mesen-
chymal stem cells into an animal model of T1DM 
mice, and demonstrated a reversal of hypergly-
cemia in 78% of cases, in addition to an increase 
in the levels of circulating insulin, glucagon, and 
amylin, although a steady climb in glucose levels 
were found later. Further, the immunomodulatory 
effects of MSCs were explained by the reduction 
in the infiltration of inflammatory cells in pancre-
atic islets, and by an increase in CD4+ regulatory 
T-cells (Tregs), which are responsible for suppress-
ing potentially deleterious T helper cells.  
Kono et al13 have shown that the systemic 
administration of human adipose-derived stromal 
cells improved glucose tolerance, increased the 
proliferation of β-cells and preserved β-cells mass 
in streptozotocin-induced T1DM mice. In-vitro 
co-culturing of islets with human adipose-derived 
stromal cells upregulated TIMP-1, which can 
prevent cytokine-induced death of β-cells. Another 
interesting mechanism was shown by Gao et al,14 
who cultured bone marrow derived mesenchy-
mal stem cells, and this conditioned media alone 
promoted islet cell proliferation in-vitro through 
Akt and Erk dependent manner. 
Mechanistically, transplanted MSCs can release 
soluble factors like cytokines, chemokines, inter-
leukins and secondary messenger molecules etc., 
which can enhance the cell survival and improve 
the tissue repair mechanisms. The immunomod-
ulatory functions of MSCs is mainly achieved 
through alteration of the secretion profile of 
dendritic cells, resulting in an increased production 
of anti-inflammatory cytokine interleukin-10 and 
a decreased production of interferon-gamma and 
interleukin-12. Furthermore, the proliferation of 
T-cells can be inhibited by MSCs through secretion 
of soluble factors like TGF-β or interleukin-10.15 
Kim et al have shown that human MSCs can inter-
act with their mechanical microenvironment and 
trigger the intracellular calcium oscillation, which 
can further trigger the transcriptional regulation of 
the pro survival cellular factors.16,17
MSCs for Diabetic Complications
In addition to the improvement of pancreatic regen-
eration, MSCs have also been shown to improve the 
complications of diabetes, such as diabetic retinop-
athy, neuropathy, nephropathy and cardiomyopa-
thy.18 Intravitreal injection of adipose tissue-derived 
stromal cells improved the electroretinogram and 
retinal histopathology through a decreased vascular 
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leakage and the down-regulation of inflammatory 
genes in streptozotocin-induced diabetic athy-
mic nude rats. This study demonstrated that the 
adipose-derived stromal cells can rescue the neural 
retina from hyperglycemia-induced degeneration, 
and improved visual function.19
Shibata et al20 transplanted bone  marrow-derived 
MSCs into hind limb skeletal muscles of 
 streptozotocin-induced rats. Although transplanted 
MSCs were not incorporated into any new struc-
tures, the MSCs were found in the gaps between the 
muscle fibres, where the secretion of vascular endo-
thelial growth factor and basic fibroblast growth 
factor was significantly increased. Furthermore, 
diabetes-induced hypoalgesia, delayed nerve 
conduction velocity, decreased sciatic nerve blood 
flow, and the abnormal sural nerve morphometry 
were normalized in MSCs’ transplanted diabetic 
animals. Thus, the paracrine effects of trans-
planted MSCs ameliorated the diabetic neuropathy. 
Although the mechanism is not clear in the study of 
Ezquer et al,21 who demonstrated that the injection 
of MSCs into diabetic mice produced histologi-
cally normal glomeruli, preventing the diabetic 
nephropathy, in addition to showing the morpho-
logically normal β-cell islets.
Zhang N et al22 demonstrated that the injec-
tion of MSCs through the femoral vein 8-weeks 
after streptozotocin injection, resulted in some 
 trans-differentiation of MSCs into cardiac 
myocytes, and increased myocardial arteriolar 
density, decreased collagen volume, leading to 
an improved cardiac function in the diabetic 
myocardium. In the same study, it was also found 
that, MSCs can induce cardiomyogenesis and 
angiogenesis through the release of paracrine 
factors like vascular endothelial growth factor, 
insulin-like  growth factor-1, adrenomedullin, 
and hepatocyte growth factor. In the random-
ized clinical trial of POSEIDON, transendocar-
dial injection of MSCs in patients with chronic 
ischemic cardiomyopathy improved the cardiac 
 remodeling and the ventricular functions by 
reducing the scar size.23
CONCLUDING REMARKS
From the pre-clinical and clinical studies, it is clear 
that treatment with MSCs improved the regener-
ation of pancreatic β-cells in T1DM through the 
release of paracrine factors and immunomodula-
tory function. Moreover, the results of several ongo-
ing clinical trials are expected to have major impact 
on the treatment of diabetes mellitus. A recent 
meta-analysis study compared several clinical 
trials utilizing various stem cells for the treatment 
of diabetes mellitus.24 Although this meta-analysis 
showed that therapy with CD34+ hematopoietic 
stem cells showed a superior outcomes, this study 
has several serious limitations, such as including 
only a small number of trials, which in turn include 
only a low number of patients, and the follow-up 
period was not sufficiently long in order to build 
any significant conclusion. Finally, although the 
results of the currently available clinical trials 
involving MSCs in treating diabetes are encourag-
ing, it is necessary to have larger, randomized, and 
double-blinded studies, with a longer duration of 
follow-up, in order to validate the findings obtained. 
REFERENCES
1. Lilly MA, Davis MF, Fabie JE, Terhune EB, Gallicano GI. 
Current stem cell based therapies in diabetes. Am J Stem 
Cells. 2016 Oct 20;5(3):87-98. PubMed PMID: 27853630; 
2. Chhabra P, Brayman KL. Stem cell therapy to cure type 1 
diabetes: from hype to hope. Stem Cells Transl Med. 2013 
May;2(5):328-36. doi: 10.5966/sctm.2012-0116. PMID: 
23572052
3. Fiorina P, Voltarelli J, Zavazava N. Immunological appli-
cations of stem cells in type 1 diabetes. Endocr Rev. 2011 
Dec;32(6):725-54. doi: 10.1210/er.2011-0008. PMID: 
21862682
4. Volarevic V, Arsenijevic N, Lukic ML, Stojkovic M.Concise 
review: Mesenchymal stem cell treatment of the complica-
tions of diabetes mellitus. Stem Cells. 2011 Jan;29(1):5-10. 
doi: 10.1002/stem.556. PMID: 21280154
5. Carlsson PO, Schwarcz E, Korsgren O, Le Blanc K. 
Preserved β-cell function in type 1 diabetes by mesenchy-
mal stromal cells. Diabetes. 2015 Feb;64(2):587-92. doi: 
10.2337/db14-0656. PMID: 25204974
6. Cai J, Wu Z, Xu X, Liao L, Chen J, Huang L, Wu W, Luo F, 
Wu C, Pugliese A, Pileggi A, Ricordi C, Tan J. Umbilical 
Cord Mesenchymal Stromal Cell With Autologous Bone 
Marrow Cell Transplantation in Established Type 1 
Diabetes: A Pilot Randomized Controlled Open-Label 
Clinical Study to Assess Safety and Impact on Insulin 
Secretion. Diabetes Care. 2016 Jan;39(1):149-57. doi: 
10.2337/dc15-0171. PMID: 26628416
7. Skyler JS, Fonseca VA, Segal KR, Rosenstock J; MSB-DM003 
Investigators..Allogeneic Mesenchymal Precursor Cells 
in Type 2 Diabetes: A Randomized, Placebo-Controlled, 
Dose-Escalation Safety and Tolerability Pilot Study. 
Diabetes Care. 2015 Sep;38(9):1742-9. doi: 10.2337/dc14-
2830. PMID: 26153271
8. Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Yin Z, Li H, 
Zhang Y, Diao Y, Li Y, Chen Y, Sun X, Fisk MB, Skidgel R, 
Holterman M, Prabhakar B, Mazzone T. Reversal of type 1 
diabetes via islet β cell regeneration following immune 
modulation by cord blood-derived multipotent stem cells. 
BMC Med. 2012 Jan 10;10:3. doi: 10.1186/1741-7015-10-3. 
PMID: 22233865
9. Lee RH, Seo MJ, Reger RL, et al. Multipotent stromal cells 
from human marrow home to and promote repair of pan-
creatic islets and renal glomeruli in diabetic NOD/scid 
mice. Proc Natl Acad Sci U S A 2006;103:17438–17443 
PMID:17088535
10. Karnieli O, Izhar-Prato Y, Bulvik S, Efrat S. Generation of 
insulin-producing cells from human bone marrow mes-
enchymal stem cells by genetic manipulation. Stem Cells. 
2007;25(11):2837-44. Epub 2007/07/07.
11. Xin Y, Jiang X, Wang Y, Su X, Sun M, Zhang L, Tan Y, 
Wintergerst KA, Li Y, Li Y. Insulin-Producing Cells 
Differentiated from Human Bone Marrow Mesenchymal 
Stem Cells In Vitro Ameliorate Streptozotocin-
Induced Diabetic Hyperglycemia. PLoS One. 2016 Jan 
12;11(1):e0145838. doi: 10.1371/journal.pone.0145838. 
PubMed PMID: 26756576; 
MSCs in diabetes mellitus Narasimman Gurusamy
4 Diabesity 2017; 3(1): 1-4. doi: 10.15562/diabesity.2017.37 www.diabesity.ejournals.ca
12. Bassi ÊJ, Moraes-Vieira PM, Moreira-Sá CS, Almeida DC, 
Vieira LM, Cunha CS, Hiyane MI, Basso AS, Pacheco-
Silva A, Câmara NO. Immune regulatory properties of 
allogeneic adipose-derived mesenchymal stem cells in the 
treatment of experimental autoimmune diabetes. Diabetes. 
2012 Oct;61(10):2534-45. PMID: 22688334
13. Kono TM, Sims EK, Moss DR, Yamamoto W, Ahn G, 
Diamond J, Tong X, Day KH, Territo PR, Hanenberg H, 
Traktuev DO, March KL, Evans-Molina C. Human adi-
pose-derived stromal/stem cells protect against STZ-
induced hyperglycemia: analysis of hASC-derived 
paracrine effectors. Stem Cells. 2014 Jul;32(7):1831-42. 
doi: 10.1002/stem.1676. PMID: 24519994
14. Gao X, Song L, Shen K, Wang H, Qian M, Niu W, Qin X. 
Bone marrow mesenchymal stem cells promote the repair 
of islets from diabetic mice through paracrine actions. 
Mol Cell Endocrinol. 2014 May 5;388(1-2):41-50. doi: 
10.1016/j.mce.2014.03.004. PMID: 24667703
15. Fiorina P, Jurewicz M, Augello A, et al. Immunomodulatory 
function of bone marrow-derived mesenchymal stem cells 
in experimental autoimmune type 1 diabetes. J Immunol 
2009;183:993–1004 pmid:19561093
16. Kim TJ, Joo C, Seong J, Vafabakhsh R, Botvinick EL, 
Berns MW, et al. Distinct mechanisms regulating mechan-
ical force-induced Ca(2)(+) signals at the plasma mem-
brane and the ER in human MSCs. eLife. 2015;4:e04876. 
Epub 2015/02/11.
17. Kim TJ, Sun J, Lu S, Qi YX, Wang Y. Prolonged mechan-
ical stretch initiates intracellular calcium oscillations in 
human mesenchymal stem cells. PLoS One. 2014 Oct 
20;9(10):e109378. doi: 10.1371/journal.pone.0109378. 
PMID: 25329052
18. Khamaisi M, Balanson SE. Stem Cells for Diabetes 
Complications: A Future Potential Cure. Rambam 
Maimonides Med J. 2017 Jan 30;8(1). doi: 10.5041/
RMMJ.10283. PMID: 28178432
19. Rajashekhar G, Ramadan A, Abburi C, Callaghan B, 
Traktuev DO, Evans-Molina C, Maturi R, Harris A, 
Kern  TS, March KL. Regenerative therapeutic potential 
of adipose stromal cells in early stage diabetic retinopathy. 
PLoS One. 2014 Jan 9;9(1):e84671. doi: 10.1371/journal.
pone.0084671. PMID: 24416262
20. Shibata T, Naruse K, Kamiya H, Kozakae M, Kondo M, 
Yasuda Y, Nakamura N, Ota K, Tosaki T, Matsuki  T, 
Nakashima E, Hamada Y, Oiso Y, Nakamura J. 
Transplantation of bone marrow-derived mesenchy-
mal stem cells improves diabetic polyneuropathy in rats. 
Diabetes. 2008 Nov;57(11):3099-107. doi: 10.2337/db08-
0031. PubMed PMID: 18728233
21. Ezquer FE, Ezquer ME, Parrau DB, Carpio D, Yañez AJ, 
Conget PA. Systemic administration of multipotent mes-
enchymal stromal cells reverts hyperglycemia and pre-
vents nephropathy in type 1 diabetic mice. Biol Blood 
Marrow Transplant. 2008 Jun;14(6):631-40. doi: 10.1016/j.
bbmt.2008.01.006. PMID: 18489988
22. Zhang N, Li J, Luo R, Jiang J, Wang JA. Bone marrow 
mesenchymal stem cells induce angiogenesis and atten-
uate the remodeling of diabetic cardiomyopathy. Exp 
Clin Endocrinol Diabetes. 2008 Feb;116(2):104-11. doi: 
10.1055/s-2007-985154. PMID: 18286426
23. Suncion VY, Ghersin E, Fishman JE, Zambrano JP, 
Karantalis V, Mandel N, Nelson KH, Gerstenblith  G, 
DiFede Velazquez DL, Breton E, Sitammagari  K, 
Schulman  IH,Taldone SN, Williams  AR, 
Sanina  C, Johnston PV, Brinker J, Altman P, 
Mushtaq M,Trachtenberg B, Mendizabal AM, Tracy M, 
Da Silva J, McNiece IK, Lardo AC, George  RT, 
Hare  JM, Heldman AW. Does transendocardial injec-
tion of mesenchymal stem cells improve myocardial 
function locally or globally?: An analysis from the 
Percutaneous Stem Cell Injection Delivery Effects 
on Neomyogenesis (POSEIDON) randomized trial. 
Circ Res. 2014 Apr 11;114(8):1292-301. doi:10.1161/
CIRCRESAHA.114.302854. PubMed PMID: 24449819;
24. El-Badawy A, El-Badri N. Clinical Efficacy of Stem Cell 
Therapy for Diabetes Mellitus: A Meta-Analysis. PLoS 
One. 2016 Apr 13;11(4):e0151938. doi: 10.1371/journal.
pone.0151938. PMID: 27073927
